[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
November 18, 1983

Aspirin-Sulfinpyrazone in Prophylaxis of Deep Venous Thrombosis in Total Hip Replacement

Author Affiliations

From the Marshfield (Wis) Clinic and the Marshfield Medical Foundation, Inc (Drs Sautter, Myers, Ray, Chen, Milbauer, Treuhaft, Plotka, and Mazza and Messrs Wenzel, Nycz, and Pierce); the Kenosha (Wis) Memorial Hospital (Dr Koch); and The Arizona Health Plan, Phoenix (Mr Larson).

JAMA. 1983;250(19):2649-2654. doi:10.1001/jama.1983.03340190051031

In postoperative hip arthroplasty patients, treatment with aspirin and sulfinpyrazone resulted in a statistically significant reduction of venographically diagnosed thrombi in the proximal veins of the leg. This reduction was most apparent in thrombi that involved the iliac vein. When compared with their placebo-treated counterparts, female patients who received the active treatment experienced a statistically significant 75% reduction of thrombosis, compared with a 32% reduction for men that was not statistically significant. There were no serious adverse effects. Factors were identified that may influence the result of drug prophylaxis trials in deep-vein thrombosis.

(JAMA 1983;250:2649-2654)